Minimizing costs for treating deep vein thrombosis: The role for fondaparinux

Journal of Thrombosis and Thrombolysis

Volumn 23, Issue 3, 2007, Pages 229-236

  Shorr, Andrew F ^a   Jackson, William L ^b   Moores, Lisa K ^b   Warkentin, Theodore E ^c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulation; Cost; Deep vein thrombosis; Enoxaparin; Fondaparinux

Indexed keywords

ENOXAPARIN; FONDAPARINUX;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; COST CONTROL; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DEEP VEIN THROMBOSIS; DRUG COST; HEALTH CARE SYSTEM; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MONTE CARLO METHOD; PRIORITY JOURNAL; RECURRENT DISEASE; SENSITIVITY ANALYSIS;

EID: 34147136696     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-9042-3     Document Type: Article

References (26)

1. Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:401S-428S
2. Knight KK, Wong J, Hauch O et al (2005) Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health 8:191-200
3. Bullano MF, Willey V, Hauch O et al (2005) Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 11:663-673
4. Wells PS, Owen C, Doucette S et al (2006) Does this patient have deep vein thrombosis? JAMA 295:199-207
5. Turpie AG, Mason JA (2002) Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. Expert Opin Pharmacother 3:575-598
6. Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis. Blood 106:2710-2715
7. Gould MK, Dembitzer AD, Sanders GD et al (1999) Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 130:789-799
8. de Lissovoy G (2001) Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective. Am J Manag Care 7:S535-S538
9. Buller HR, Davidson BL, Decousus H et al (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med 140:867-873
10. Buller HR, Davidson BL, Decousus H et al (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695-1702
11. Prandoni P, Siragusa S, Girolami B et al (2005) The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: A prospective cohort study. Blood 106:3049-3054
12. Gruel Y, Pouplard C, Nguyen P et al (2003) Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 121:786-792
13. Siegel JE, Weinstein MC, Russell LB et al (1996) Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276:1339-1341
14. Merli G, Spiro TE, Olsson CG et al (2001) Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134:191-202
15. Savi P, Chong BH, Greinacher A et al (2005) Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicenter study with unfractionated heparin. Blood 105:139-144
16. Warkentin TE, Cook RJ, Marder VJ et al (2005) Anti-platelet factor 4/ heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106:3791-3796
17. Kuo KH, Kovacs MJ (2005) Fondaparinux: A potential new therapy for HIT. Hematology 10:271-275
18. Kovacs MJ (2005) Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 93:999-1000
19. Harenberg J, Jorg I, Fenyvesi T (2004) Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 89:1017-1018
20. Ranze O, Eichner A, Lubenow N et al (2000) The use of low-molecular-weight heparins in heparin-induced thrombocytopenia (HIT): a cohort study [abstr]. Ann Hematol 79(Suppl 1):P198
21. Aujesky D, Smith KJ, Cornuz J et al (2005) Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 128:1601-1610
22. McGarry LJ, Thompson D, Weinstein MC et al (2004) Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care 10:632-642
23. Spruill WJ, Wade WE, Leslie RB (2004) A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty. Am J Ther 11:3-8
24. Sullivan SD, Davidson BL, Kahn SR et al (2004) A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: Use in patients undergoing major orthopaedic surgery. Pharmacoeconomics 22:605-620
25. Dranitsaris G, Kahn SR, Stumpo C et al (2004) Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. Am J Cardiovasc Drugs 4:325-333
26. Annemans L, Minjoulat-Rey MC, De Knock M et al (2004) Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium. Acta Clin Belg 59:346-357